Clinical Trials // Congenital Achromatopsia // Genetic mutation // Inherited Retinal Degeneration // Kimberly Stepien // Past // Sep 30 2020
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Sponsor: Applied Genetic Technologies Corp